Clostridium difficile: moving beyond antimicrobial therapy

Affiliations

Comment

Amesh A Adalja et al. Crit Care. 2010.

. 2010;14(5):320.

doi: 10.1186/cc9249. Epub 2010 Sep 16.

¹ Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

No abstract available

Comment on

Treatment with monoclonal antibodies against Clostridium difficile toxins.
Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD Jr, Leney M, Sloan S, Hay CA, Ambrosino DM. Lowy I, et al. N Engl J Med. 2010 Jan 21;362(3):197-205. doi: 10.1056/NEJMoa0907635. N Engl J Med. 2010. PMID: 20089970 Clinical Trial.

1. Sachin Yende, editor. Evidence-Based Medicine Journal Club. University of Pittsburgh Department of Critical Care Medicine;

1. Dubberke ER, Butler AM, Reske KA, Agniel D, Olsen MA, D'Angelo G, McDonald LC, Fraser VJ. Attributable outcomes of endemic Clostridium difficile-associated disease in nonsurgical patients. Emerg Infect Dis. 2008;14:1031–1038. doi: 10.3201/eid1407.070867. - DOI - PMC - PubMed
1. Dubberke ER, Reske KA, Olsen MA, McDonald LC, Fraser VJ. Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis. 2008;46:497–504. doi: 10.1086/526530. - DOI - PubMed
1. Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect. 2008;70:298–304. doi: 10.1016/j.jhin.2008.08.012. - DOI - PubMed
1. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD Jr, Leney M, Sloan S, Hay CA, Ambrosino DM. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362:197–205. doi: 10.1056/NEJMoa0907635. - DOI - PubMed
1. Kyne L. Clostridium difficile--beyond antibiotics. N Engl J Med. 2010;362:264–265. doi: 10.1056/NEJMe0910055. - DOI - PubMed